Axis-Shield's testosterone test gains FDA approval:
This article was originally published in Clinica
Executive Summary
Anglo-Norwegian firm Axis-Shield has received FDA approval to market its testosterone assay in the US using Abbott Laboratories AxSYM range of laboratory analysers. Axis-Shield will manufacture the test at its Dundee, Scotland facilities, having launched the testosterone test in non-US markets earlier this year. Detecting abnormal levels of testosterone can help diagnose conditions such as infertility, pituitary disease, obesity, adrenal disease and polycystic ovary syndrome. Axis-Shield claims there are already 17,000 AxSYM analysers placed in hospitals and laboratories worldwide, and plans to extend its range of AxSYM-based assays under its agreement with Abbott.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.